« Previous
Next »
Titles
- Tax administration: IRS oversight of hospitals’ tax-exempt status : testimony before the Subcommittee on Oversight, Committee on Ways and Means, House of Representatives1
- Technical assistance brief: implementation of inflation-indexed rebates for Part B drugs1
- Technical considerations for medical devices with physiologic closed-loop control technology: guidance for industry and Food and Drug Administration staff1
- Technical performance assessment of quantitative imaging in radiological device premarket submissions: guidance for industry and Food and Drug Administration staff1
- Technical specifications for submitting clinical trial data sets for treatment of noncirrhotic nonalcoholic steatohepatitis (NASH)2
- Technology and disability: the relationship between broadband access and disability insurance awards1
- Telehealth was critical for providing services to Medicare beneficiaries during the first year of the COVID-19 pandemic1
- Testing of glycerin, propylene glycol, maltitol solution, hydrogenated starch hydrolysate, sorbitol solution, and other high-risk drug components for diethylene glycol and ethylene glycol: guidance for industry1
- Tezepelumab for severe asthma: final report1
- The Bipartisan Safer Communities Act: where things stand on the Medicaid and CHIP provisions1
- The COVID-19 Provider Relief Fund: following how the US Department of Health and Human Services distributed $178 billion1
- The Colorado Multi-Payer Collaborative: a framework for integration of whole-person care1
- The Food and Drug Administration needs to improve the premarket tobacco application review process for electronic nicotine delivery systems to protect public health1
- The Medicare Advantage quality bonus program: high cost for uncertain gain1
- The Medicare and Medicaid Improvement Funds: budgetary history and projections1
- The Medicare financing conundrum: revenues, spending, and short- and long-term fiscal challenges1
- The Provider Relief Fund helped select nursing homes maintain services during the COVID-19 pandemic, but some found guidance difficult to use1
- The Strategic National Stockpile was not positioned to respond effectively to the COVID-19 pandemic1
- The consistently low percentage of Medicare enrollees receiving medication to treat their opioid use disorder remains a concern1
- The coordinated specialty care transition study: final report1